Skip to main content

Information for COVID-19 Therapeutics Providers

All COVID-19 Therapeutics have transitioned to the commercial market as of December 2023. COVID-19 Therapeutics are no longer available for distribution from U.S. Health and Human Services/Administration for Strategic Preparedness and Response (ASPR) with the exception of certain federal entities. Information on purchasing COVID-19 Therapeutics and this transition can be found on the ASPR website: ASPR Transition Guide.

For more information on COVID-19 Therapeutics, please contact ASPR at covid19.therapeutics@hhs.gov.

On this page:

Patient Assistance Programs

Patient Assistance Programs are available for PAXLOVID (nirmatrelvir tablets; ritonavir tablets), Lagevrio (molnupiravir), and Veklury (remdesivir). 

PAXLOVID (nirmatrelvir/ritonavir):

For eligible patients, PAXCESS Patient Support Program offers personalized resources to help get PAXLOVID.

For patients who don’t meet the requirements for the PAXCESS Co-Pay Savings Program, other resources may be available.

To qualify for free PAXLOVID through the program until December 31, 2024, patients must be:

  • Uninsured and do not have a prescription drug benefit at the time they fill their prescription
  • Medicare beneficiaries
  • Medicaid beneficiaries

For more information on accessing PAXLOVID, please visit PAXCESS™ | PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets) or call 1-877-219-7225.

Lagevrio (molnupiravir):

The Merck Patient Assistance Program provides Lagevrio free of charge to patients who meet its eligibility criteria and who, without assistance, could not otherwise afford the product.

Learn more at  Merck Programs to Help Those in Need - Product (merckhelps.com) or call 1-800-727-5400 to see eligibility criteria.

Veklury (remdesivir):

The Gilead Advancing Access Program offers information and resources to help patients understand coverage and financial options for prescribed Gilead medication.

For more information, please visit the Advancing Access Program website or call 1-800-226-2056.

Health Partner Ordering Portal (HPOP) Reporting for United States Government (USG) Provided Therapeutics

Please continue to report ONLY USG supplied therapeutics until they run out or expire. Continue to follow HPOP guidelines on reporting, dispositions, and transfers. 

Reporting is required in HPOP for each USG supplied product if your facility has inventory.  Reporting is required at least twice a month on the 15th and at the end of the month. Please be sure to enter both administered (even if it is zero) and on-hand count for all products that are in your inventory.

If you have any questions on reporting, please contact HPOP Support at HPOP.Support@hhs.gov or call 833-868-6386.  

COVID-19 Therapeutics and Test to Treat Locator Tools

To find locations with COVID-19 therapeutics on hand and Test to Treat  locations, please visit the following sites:

The USG has developed a mechanism for COVID-19 Therapeutic providers to report commercial treatment locations voluntarily that will be visible in an expanded treatments locator tool. Sites can voluntarily upload commercially acquired inventory data for Paxlovid (nirmatrelvir tablets; ritonavir tablets), Lagevrio (molnupiravir), and outpatient Veklury (remdesivir) via HPOP.

  • It is encouraged sites to report commercial therapeutics as often as possible; reporting commercially distributed therapeutics at least every 14 days is requested to ensure the locator remains accurate.
  • After 60 days, sites will fall off the locator until commercial inventory is reported again.

Learn more in the COVID-19 Therapeutics Transition Guide.

Currently Authorized or Approved Oral COVID-19 Therapeutics

The links below contain a list of product-specific resources.

Shelf-life extension information can be found individually in each of the applicable product-specific sections, as well as in the Shelf-Life Extensions section.

COVID-19 Therapeutics That Are No Longer Authorized

The U.S. Government recommends that facilities and providers with unauthorized therapeutics retain all product in the event that future variants which are neutralized by unauthorized therapeutics become more prevalent in the U.S. in the future. Retained product must be appropriately held in accordance with storage conditions detailed in the corresponding authorized Fact Sheet for Health Care Providers and the Letter of Authorization.  If product is no longer able to be retained or if it has expired, providers are required to report disposition of product in HPOP. 

Monoclonal Antibody (mAb) Products

  • Bamlanivimab + Etesevimab (Lilly) 
  • Casirivimab + Imdevimab (Regeneron) 
  • Sotrovimab (GlaxoSmithKline) 
  • Bebtelovimab (Lilly)

Long-Acting Antibody (LAAB) Product

  • Evusheld: tixagevimab + cilgavimab (AstraZeneca)

For more information on these products, please see the Food and Drug Administration (FDA) website on Emergency Use Authorizations.

Shelf-Life Extensions

Important Links